Extended Data Fig. 5: Neither HLA-I heterozygosity nor HLA-I evolutionary divergence is associated with prognosis in TCGA lung cancer patients.
From: Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy
a, Full heterozygosity at HLA-I (red) is not associated with prognosis in TCGA lung cancer patients; P = 0.38, two-sided log-rank test. b, High mean HED is not associated with prognosis in patients from Extended Data Fig. 4a; P = 0.48, log-rank test. c, High mean HED (red) is not associated with prognosis in TCGA lung cancer patients fully heterozygous at HLA-I; P = 0.51, two-sided log-rank test.
